SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

36 Product Life Timeline • Due to settlement agreements dated between 2012 - 2013, 4 generics can enter in 2020, but do not apply to Silenor ® OTC • Teva / Actavis & Mylan entry: January 1, 2020 • Par and Zydus entry: 180 days after first commercial launch by a third party • Current LCM efforts are focused on exploring strategic alternatives for a potential OTC version of Silenor ® • Certain generics to enter the market in 2020 • Teva /Actavis or Mylan may enter as early as Jan. 2020 • Par and Zydus will have to wait 6 months after the first commercial launch by either Teva /Actavis or Mylan • Company is currently exploring strategic alternatives for a potential OTC version of Silenor ® 2016 2017 2018 2019 2020 2026 2030 2033 2034 Patents to cover OTC to 2030 Litigation resulted in 4 generics to launch in 2020 Teva/Actavis & Mylan January 1, 2020 Par and Zydus: 180 days after 1st commercial launch by 3rd Party Silenor ® Life Cycle Management